| DTI |
2026-08-25 16:30 |
2026-08-24 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
M - OptEx |
— |
+125.0K |
194.3K |
+180% |
— |
| DTI |
2026-08-25 16:30 |
2026-08-24 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
S - Sale+OE |
$26.91 |
-125.0K |
69.3K |
-64% |
-$3.36M |
| DMTI |
2026-03-09 |
2026-03-05+ |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
M - OptEx |
— |
+300.0K |
170.7K |
New |
— |
| DMTI |
2026-03-09 |
2026-03-05+ |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
S - Sale+OE |
$30.30 |
-300.0K |
69.3K |
-81% |
-$9.09M |
| M |
2026-02-24 |
2026-02-20 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
S - Sale |
$35.31 |
-45.5K |
84.3K |
-35% |
-$1.61M |
| DT |
2026-01-07 |
2026-01-05 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
S - Sale |
$33.25 |
-6,000 |
73.5K |
-8% |
-$199.5K |
| DT |
2026-01-07 |
2026-01-07 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
A - Grant |
— |
+25.5K |
99.0K |
+35% |
— |
| MI |
2025-08-25 |
2025-08-21+ |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
S - Sale |
$24.72 |
-100.0K |
77.0K |
-57% |
-$2.47M |
| D |
2025-03-28 |
2025-03-26 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
M - OptEx |
$0.00 |
+45.5K |
79.5K |
+134% |
$0 |
| DI |
2025-03-28 |
2025-03-26 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
A - Grant |
$0.00 |
+19.3K |
169.3K |
+13% |
$0 |
| DI |
2025-03-26 |
2025-03-24 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
M - OptEx |
— |
+150.0K |
150.0K |
New |
— |
|
2025-01-07 |
2025-01-07 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
A - Grant |
— |
+34.0K |
34.0K |
New |
— |
| DI |
2024-03-27 |
2024-03-26 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
S - Sale+OE |
$21.50 |
-190.5K |
0 |
-100% |
-$4.10M |
| DI |
2024-03-27 |
2024-03-26 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
F - Tax |
$22.72 |
-11.2K |
190.5K |
-6% |
-$254.4K |
| DI |
2024-03-27 |
2024-03-26 |
NAMS |
NewAmsterdam Pharma Co N.V. |
Kastelein Johannes Jacob Pieter |
CSO, Dir |
M - OptEx |
— |
+201.7K |
201.7K |
New |
— |